Savara’s MOLBREEVI: Strong Phase 3 Data and Financial Positioning Signal High Approval Likelihood and Market Potential

Analyst Francois Brisebois from LifeSci Capital maintained a Buy rating on Savara and keeping the price target at $11.00.

Francois Brisebois has given his Buy rating due to a combination of factors surrounding Savara’s progress and potential. The company is on track with its Biologics License Application (BLA) resubmission for MOLBREEVI, expected in December, and plans to submit a Marketing Authorization Application (MAA) in the EU and UK in the first quarter of 2026. The strong Phase 3 data, published in the New England Journal of Medicine, suggests a high likelihood of approval, which is further supported by positive feedback from key opinion leaders (KOLs) regarding MOLBREEVI’s potential use across all patient groups.
Additionally, Savara’s recent financial strengthening positions the company well for executing its plans, including a potential launch in 2026. The robust safety and efficacy data, with significant improvements in primary endpoints and durability of effect, bolster confidence in the product’s approval. The KOLs’ willingness to offer MOLBREEVI to a wide range of patients, even those with severe conditions, indicates a promising market opportunity, potentially making it a blockbuster in the U.S. market.